Italy suspends use of AstraZeneca vaccine for people under 60 year old

Italy on Friday suspended the use of the AstraZeneca vaccine for people under 60 years old, health officials announced at a weekly press conference on the Covid-19 pandemic.

The move came after an 18-year-old woman died of a blood clot Thursday after receiving an initial dose of AstraZeneca on May 25, Xinhua reported.

According to local media reports, the young woman suffered from autoimmune thrombocytopenia (meaning that she had a low blood platelet count) and was on double hormone therapy.

An investigation is underway to find out whether she had disclosed this information during the vaccine intake procedure, Italian news agency Ansa reported.

"The epidemiological scenario has changed, and so has the relationship between the benefits of vaccination and the potential risk of unusual blood clots," Franco Locatelli, coordinator of the Technical Scientific Committee (CTS) which gives advice to the government on how to handle the pandemic, said at the press conference.

The CTS recommends that people under 60 who received an initial dose of AstraZeneca be given a different vaccine for their second dose, Locatelli said, adding that this move represents "an excess of caution".

Over 40.7 million doses of vaccine have been administered in Italy and over 13.7 million people, or 25 percent of the population aged over 12, have been fully inoculated, according to the latest tally from the Ministry of Health on Friday.



(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel